Geographic Atrophy

The Therapeutic Goods Administration (TGA) has approved the first treatment for geographic atrophy (GA) in Australia, Syfovre from Apellis Pharmaceuticals,...

Patients diagnosed with late-stage age-related macular degeneration in Australia have entirely different prospects, depending on what form they have. But...

Researchers at the National Institutes of Health (NIH) have found that taking a daily supplement containing antioxidant vitamins and minerals...

Macular Disease Foundation Australia (MDFA) has launched Eye Connect, a comprehensive support service for people living with macular disease and...

Optometrists have an opportunity to maximise care for their patients after they depart the consulting room thanks to patient support...

People often turn to supplements or superfoods to ward off macular disease or prevent its progression, but new Australian nutritional...

The Australian eyecare sector is challenging the idea that vision loss with age is inevitable. This, combined with cutting-edge research...

RANZCO’s Referral Pathway for Age-Related Macular Degeneration (AMD) Management has been updated as Australia gears up for the first approved...

Apellis Pharmaceuticals has responded to “positive” 24-month data for its pioneering geographic atrophy (GA) therapy published in The Lancet, demonstrating...

An investigation into rare events of retinal vasculitis linked to Apellis Pharmaceutical’s new therapy, SYFOVRE, for geographic atrophy (GA) has...